Chavez-Tapia NC, Méndez-Sánchez N

Language: English
References: 14
Page: 163-165
PDF size: 56.76 Kb.

Text Extraction

The approval of potentially effective treatments for serious and life-threatening conditions represents a particularly difficult arena for drug developers, regulators and physicians. Hanging in the balance is the need to provide a timely treatment alternative to an otherwise untreatable and serious condition, while also assuring that the proposed treatment is sufficiently safe to preserve the overall wellbeing of the patient. This is a particularly difficult decision, as weighting the risk and benefits must be done fast and over a much finer scale than in situations where effective treatments are available.

REFERENCES

1. Landells LJ, Naidoo B, Robertson J, Clark P. NICE guidance on pirfenidone for treating idiopathic pulmonary fibrosis. Lancet Respir Med 2013; 1: 191-2.

2. Navarro-Partida J, Martinez-Rizo AB, Gonzalez-Cuevas J, Arrevillaga-Boni G, Ortiz-Navarrete V, Armendariz-Borunda J. Pirfenidone restricts Th2 differentiation in vitro and limits Th2 response in experimental liver fibrosis. Eur J Pharmacol 2012; 678:71-7.

3. Armendariz-Borunda J, Islas-Carbajal MC, Meza-Garcia E, Rincon AR, Lucano S, Sandoval AS, et al. A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut 2006; 55: 1663-5.

4. Jiang C, Huang H, Liu J, Wang Y, Lu Z, Xu Z. Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials. PLoS One 2012; 7: e47024.

5. Klein R. A new paradigm for funding medical research. Stem Cells Transl Med 2012; 1: 3-5.

6. Puggal MA, Schully SD, Srinivas PR, Papanicolaou GJ, Jaquish CE, Fabsitz RR. Translation of genetics research to clinical medicine: the national heart, lung, and blood institute perspective. Circ Cardiovasc Genet 2013;6:634-639.

7. Garattini S, Bertele V. Efficacy, safety, and cost of new anticancer drugs. Bmj 2002; 325: 269-71.

8. Apolone G. Clinical and outcome research in oncology. The need for integration. Health Qual Life Outcomes 2003; 1: 3.

9. Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: metaepidemiological study. Bmj 2013; 346: f2304.

10. Inthout J, Ioannidis JP, Borm GF. Obtaining evidence by a single well-powered trial or several modestly powered trials. Stat Methods Med Res 2012; Oct 14. [Epub ahead of print].

11. Oberfeld D, Franke T. Evaluating the robustness of repeated measures analyses: the case of small sample sizes and nonnormal data. Behav Res Methods 2013; 45: 792-812.

12. Mendez-Sanchez N, Garcia-Villegas E, Merino-Zeferino B, Ochoa-Cruz S, Villa AR, Madrigal H, et al. Liver diseases in Mexico and their associated mortality trends from 2000 to 2007: A retrospective study of the nation and the federal states. Ann Hepatol 2010; 9: 428-38.

13. Ledford H. Pharma scrambles to fast-track drugs. Nature 2013; 502: 20.

14. Rich EC. From methods to policy: Primum non nocere: reconciling patient-centered outcomes with evidence-based care. J Comp Eff Res 2013; 2: 107-8.